This activity has expired. Credit is no longer available.
This activity is supported by unrestricted educational grants from AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Novartis Pharmaceutical Corporation; and Taiho Oncology, Inc.
The Role of the Advanced Practitioner in Maintaining Adherence in Patients on Oral Oncolytics
Almost 40% of the total cost of targeted therapies in the US are now for oral formulations, up from 26% in 2010. This increase calls for APs to act as practice-to-patient liaison with limited resources. This education will focus on how APs can overcome a variety of barriers for patient nonadherence to oral therapies and encourage patients to continue their regimens.
Please visit the Oral Oncolytics Adherence Knowledge Center at: https://www.jadproce.com/2017/oral-oncolytics/
Chapter 1
Introduction and Overview
Chapter 2
Benefits of Oral Oncolytic Therapy
Chapter 3
Patient Adherence to Therapy
Chapter 4
Case Study
Chapter 5
Therapy Adherence Barriers
Chapter 6
Monitoring Patient Adherence
Chapter 7
Financial Burden of Oral Oncolytics
Chapter 8
Supporting Patients on Oral Oncolytics
Chapter 9
Conclusion
These activities, certified for CME/CE/CPE credit, are jointly provided by
  |